Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co. debt to equity ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Bristol-Myers Squibb Co. debt to equity ratio (including operating lease liability) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co. debt to capital ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Bristol-Myers Squibb Co. debt to capital ratio (including operating lease liability) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co. debt to assets ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Bristol-Myers Squibb Co. debt to assets ratio (including operating lease liability) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co. financial leverage ratio increased from 2019 to 2020 but then slightly decreased from 2020 to 2021. |
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co. interest coverage ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co. fixed charge coverage ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Debt to Equity
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | 4,948 | 2,340 | 3,346 | 1,703 | 987 | |
Long-term debt, excluding current portion | 39,605 | 48,336 | 43,387 | 5,646 | 6,975 | |
Total debt | 44,553 | 50,676 | 46,733 | 7,349 | 7,962 | |
Total Bristol-Myers Squibb Company shareholders’ equity | 35,946 | 37,822 | 51,598 | 14,031 | 11,741 | |
Solvency Ratio | ||||||
Debt to equity1 | 1.24 | 1.34 | 0.91 | 0.52 | 0.68 | |
Benchmarks | ||||||
Debt to Equity, Competitors2 | ||||||
Abbott Laboratories | 0.50 | 0.57 | 0.58 | 0.64 | 0.90 | |
CVS Health Corp. | 0.75 | 0.93 | 1.07 | 1.26 | 0.72 | |
Danaher Corp. | 0.49 | 0.53 | 0.72 | 0.35 | 0.40 | |
Elevance Health Inc. | 0.64 | 0.60 | 0.63 | 0.67 | 0.75 | |
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Medtronic PLC | 0.51 | 0.49 | 0.51 | 0.51 | 0.66 | |
UnitedHealth Group Inc. | 0.64 | 0.66 | 0.71 | 0.71 | 0.66 | |
Debt to Equity, Sector | ||||||
Health Care Equipment & Services | 0.65 | 0.72 | 0.74 | 0.71 | 0.67 | |
Debt to Equity, Industry | ||||||
Health Care | 0.79 | 0.93 | 0.93 | 0.86 | 0.81 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Debt to equity = Total debt ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= 44,553 ÷ 35,946 = 1.24
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Bristol-Myers Squibb Co. debt to equity ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to Equity (including Operating Lease Liability)
Bristol-Myers Squibb Co., debt to equity (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | 4,948 | 2,340 | 3,346 | 1,703 | 987 | |
Long-term debt, excluding current portion | 39,605 | 48,336 | 43,387 | 5,646 | 6,975 | |
Total debt | 44,553 | 50,676 | 46,733 | 7,349 | 7,962 | |
Current operating lease liabilities | 169 | 164 | 133 | — | — | |
Non-current operating lease liabilities | 874 | 833 | 672 | — | — | |
Total debt (including operating lease liability) | 45,596 | 51,673 | 47,538 | 7,349 | 7,962 | |
Total Bristol-Myers Squibb Company shareholders’ equity | 35,946 | 37,822 | 51,598 | 14,031 | 11,741 | |
Solvency Ratio | ||||||
Debt to equity (including operating lease liability)1 | 1.27 | 1.37 | 0.92 | 0.52 | 0.68 | |
Benchmarks | ||||||
Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
Abbott Laboratories | 0.54 | 0.61 | 0.61 | 0.64 | 0.90 | |
CVS Health Corp. | 1.01 | 1.23 | 1.39 | 1.26 | 0.72 | |
Danaher Corp. | 0.52 | 0.56 | 0.74 | 0.35 | 0.40 | |
Elevance Health Inc. | 0.67 | 0.63 | 0.65 | 0.67 | 0.75 | |
Intuitive Surgical Inc. | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
Medtronic PLC | 0.53 | 0.51 | 0.51 | 0.51 | 0.66 | |
UnitedHealth Group Inc. | 0.70 | 0.73 | 0.77 | 0.71 | 0.66 | |
Debt to Equity (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | 0.73 | 0.81 | 0.83 | 0.71 | 0.67 | |
Debt to Equity (including Operating Lease Liability), Industry | ||||||
Health Care | 0.84 | 0.99 | 0.99 | 0.86 | 0.81 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= 45,596 ÷ 35,946 = 1.27
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to equity ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Bristol-Myers Squibb Co. debt to equity ratio (including operating lease liability) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to Capital
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | 4,948 | 2,340 | 3,346 | 1,703 | 987 | |
Long-term debt, excluding current portion | 39,605 | 48,336 | 43,387 | 5,646 | 6,975 | |
Total debt | 44,553 | 50,676 | 46,733 | 7,349 | 7,962 | |
Total Bristol-Myers Squibb Company shareholders’ equity | 35,946 | 37,822 | 51,598 | 14,031 | 11,741 | |
Total capital | 80,499 | 88,498 | 98,331 | 21,380 | 19,703 | |
Solvency Ratio | ||||||
Debt to capital1 | 0.55 | 0.57 | 0.48 | 0.34 | 0.40 | |
Benchmarks | ||||||
Debt to Capital, Competitors2 | ||||||
Abbott Laboratories | 0.34 | 0.36 | 0.37 | 0.39 | 0.47 | |
CVS Health Corp. | 0.43 | 0.48 | 0.52 | 0.56 | 0.42 | |
Danaher Corp. | 0.33 | 0.35 | 0.42 | 0.26 | 0.29 | |
Elevance Health Inc. | 0.39 | 0.38 | 0.39 | 0.40 | 0.43 | |
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Medtronic PLC | 0.34 | 0.33 | 0.34 | 0.34 | 0.40 | |
UnitedHealth Group Inc. | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | |
Debt to Capital, Sector | ||||||
Health Care Equipment & Services | 0.39 | 0.42 | 0.43 | 0.42 | 0.40 | |
Debt to Capital, Industry | ||||||
Health Care | 0.44 | 0.48 | 0.48 | 0.46 | 0.45 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Debt to capital = Total debt ÷ Total capital
= 44,553 ÷ 80,499 = 0.55
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Bristol-Myers Squibb Co. debt to capital ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to Capital (including Operating Lease Liability)
Bristol-Myers Squibb Co., debt to capital (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | 4,948 | 2,340 | 3,346 | 1,703 | 987 | |
Long-term debt, excluding current portion | 39,605 | 48,336 | 43,387 | 5,646 | 6,975 | |
Total debt | 44,553 | 50,676 | 46,733 | 7,349 | 7,962 | |
Current operating lease liabilities | 169 | 164 | 133 | — | — | |
Non-current operating lease liabilities | 874 | 833 | 672 | — | — | |
Total debt (including operating lease liability) | 45,596 | 51,673 | 47,538 | 7,349 | 7,962 | |
Total Bristol-Myers Squibb Company shareholders’ equity | 35,946 | 37,822 | 51,598 | 14,031 | 11,741 | |
Total capital (including operating lease liability) | 81,542 | 89,495 | 99,136 | 21,380 | 19,703 | |
Solvency Ratio | ||||||
Debt to capital (including operating lease liability)1 | 0.56 | 0.58 | 0.48 | 0.34 | 0.40 | |
Benchmarks | ||||||
Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
Abbott Laboratories | 0.35 | 0.38 | 0.38 | 0.39 | 0.47 | |
CVS Health Corp. | 0.50 | 0.55 | 0.58 | 0.56 | 0.42 | |
Danaher Corp. | 0.34 | 0.36 | 0.43 | 0.26 | 0.29 | |
Elevance Health Inc. | 0.40 | 0.39 | 0.40 | 0.40 | 0.43 | |
Intuitive Surgical Inc. | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
Medtronic PLC | 0.35 | 0.34 | 0.34 | 0.34 | 0.40 | |
UnitedHealth Group Inc. | 0.41 | 0.42 | 0.44 | 0.41 | 0.40 | |
Debt to Capital (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | 0.42 | 0.45 | 0.45 | 0.42 | 0.40 | |
Debt to Capital (including Operating Lease Liability), Industry | ||||||
Health Care | 0.46 | 0.50 | 0.50 | 0.46 | 0.45 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 45,596 ÷ 81,542 = 0.56
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to capital ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Bristol-Myers Squibb Co. debt to capital ratio (including operating lease liability) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to Assets
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | 4,948 | 2,340 | 3,346 | 1,703 | 987 | |
Long-term debt, excluding current portion | 39,605 | 48,336 | 43,387 | 5,646 | 6,975 | |
Total debt | 44,553 | 50,676 | 46,733 | 7,349 | 7,962 | |
Total assets | 109,314 | 118,481 | 129,944 | 34,986 | 33,551 | |
Solvency Ratio | ||||||
Debt to assets1 | 0.41 | 0.43 | 0.36 | 0.21 | 0.24 | |
Benchmarks | ||||||
Debt to Assets, Competitors2 | ||||||
Abbott Laboratories | 0.24 | 0.26 | 0.27 | 0.29 | 0.37 | |
CVS Health Corp. | 0.24 | 0.28 | 0.31 | 0.37 | 0.28 | |
Danaher Corp. | 0.27 | 0.28 | 0.35 | 0.20 | 0.23 | |
Elevance Health Inc. | 0.24 | 0.23 | 0.26 | 0.27 | 0.28 | |
Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Medtronic PLC | 0.28 | 0.27 | 0.28 | 0.28 | 0.34 | |
UnitedHealth Group Inc. | 0.22 | 0.22 | 0.23 | 0.24 | 0.23 | |
Debt to Assets, Sector | ||||||
Health Care Equipment & Services | 0.26 | 0.28 | 0.29 | 0.29 | 0.28 | |
Debt to Assets, Industry | ||||||
Health Care | 0.29 | 0.31 | 0.32 | 0.31 | 0.31 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Debt to assets = Total debt ÷ Total assets
= 44,553 ÷ 109,314 = 0.41
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Bristol-Myers Squibb Co. debt to assets ratio deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Debt to Assets (including Operating Lease Liability)
Bristol-Myers Squibb Co., debt to assets (including operating lease liability) calculation, comparison to benchmarks
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Short-term debt obligations | 4,948 | 2,340 | 3,346 | 1,703 | 987 | |
Long-term debt, excluding current portion | 39,605 | 48,336 | 43,387 | 5,646 | 6,975 | |
Total debt | 44,553 | 50,676 | 46,733 | 7,349 | 7,962 | |
Current operating lease liabilities | 169 | 164 | 133 | — | — | |
Non-current operating lease liabilities | 874 | 833 | 672 | — | — | |
Total debt (including operating lease liability) | 45,596 | 51,673 | 47,538 | 7,349 | 7,962 | |
Total assets | 109,314 | 118,481 | 129,944 | 34,986 | 33,551 | |
Solvency Ratio | ||||||
Debt to assets (including operating lease liability)1 | 0.42 | 0.44 | 0.37 | 0.21 | 0.24 | |
Benchmarks | ||||||
Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
Abbott Laboratories | 0.26 | 0.27 | 0.28 | 0.29 | 0.37 | |
CVS Health Corp. | 0.33 | 0.37 | 0.40 | 0.37 | 0.28 | |
Danaher Corp. | 0.28 | 0.29 | 0.36 | 0.20 | 0.23 | |
Elevance Health Inc. | 0.25 | 0.24 | 0.27 | 0.27 | 0.28 | |
Intuitive Surgical Inc. | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | |
Medtronic PLC | 0.29 | 0.28 | 0.28 | 0.28 | 0.34 | |
UnitedHealth Group Inc. | 0.24 | 0.24 | 0.26 | 0.24 | 0.23 | |
Debt to Assets (including Operating Lease Liability), Sector | ||||||
Health Care Equipment & Services | 0.29 | 0.31 | 0.32 | 0.29 | 0.28 | |
Debt to Assets (including Operating Lease Liability), Industry | ||||||
Health Care | 0.31 | 0.34 | 0.34 | 0.31 | 0.31 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 45,596 ÷ 109,314 = 0.42
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Debt to assets ratio (including operating lease liability) | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Bristol-Myers Squibb Co. debt to assets ratio (including operating lease liability) deteriorated from 2019 to 2020 but then slightly improved from 2020 to 2021. |
Financial Leverage
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Total assets | 109,314 | 118,481 | 129,944 | 34,986 | 33,551 | |
Total Bristol-Myers Squibb Company shareholders’ equity | 35,946 | 37,822 | 51,598 | 14,031 | 11,741 | |
Solvency Ratio | ||||||
Financial leverage1 | 3.04 | 3.13 | 2.52 | 2.49 | 2.86 | |
Benchmarks | ||||||
Financial Leverage, Competitors2 | ||||||
Abbott Laboratories | 2.10 | 2.21 | 2.18 | 2.20 | 2.47 | |
CVS Health Corp. | 3.10 | 3.32 | 3.48 | 3.37 | 2.52 | |
Danaher Corp. | 1.84 | 1.92 | 2.05 | 1.70 | 1.77 | |
Elevance Health Inc. | 2.70 | 2.61 | 2.44 | 2.51 | 2.66 | |
Intuitive Surgical Inc. | 1.14 | 1.15 | 1.18 | 1.17 | 1.22 | |
Medtronic PLC | 1.81 | 1.79 | 1.79 | 1.80 | 1.98 | |
UnitedHealth Group Inc. | 2.96 | 3.01 | 3.02 | 2.94 | 2.91 | |
Financial Leverage, Sector | ||||||
Health Care Equipment & Services | 2.53 | 2.61 | 2.57 | 2.49 | 2.40 | |
Financial Leverage, Industry | ||||||
Health Care | 2.74 | 2.95 | 2.89 | 2.78 | 2.65 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Financial leverage = Total assets ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= 109,314 ÷ 35,946 = 3.04
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Bristol-Myers Squibb Co. financial leverage ratio increased from 2019 to 2020 but then slightly decreased from 2020 to 2021. |
Interest Coverage
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings (loss) attributable to BMS | 6,994 | (9,015) | 3,439 | 4,920 | 1,007 | |
Add: Net income attributable to noncontrolling interest | 20 | 20 | 21 | 27 | (32) | |
Add: Income tax expense | 1,084 | 2,124 | 1,515 | 1,021 | 4,156 | |
Add: Interest expense | 1,334 | 1,420 | 656 | 183 | 196 | |
Earnings before interest and tax (EBIT) | 9,432 | (5,451) | 5,631 | 6,151 | 5,327 | |
Solvency Ratio | ||||||
Interest coverage1 | 7.07 | -3.84 | 8.58 | 33.61 | 27.18 | |
Benchmarks | ||||||
Interest Coverage, Competitors2 | ||||||
Abbott Laboratories | 16.41 | 10.10 | 7.09 | 4.48 | 3.47 | |
CVS Health Corp. | 5.16 | 4.36 | 3.96 | 1.54 | 8.79 | |
Danaher Corp. | 32.92 | 17.35 | 31.44 | 21.92 | 19.06 | |
Elevance Health Inc. | 10.93 | 8.96 | 9.02 | 7.73 | 6.36 | |
Intuitive Surgical Inc. | — | — | — | — | — | |
Medtronic PLC | 5.21 | 4.71 | 4.60 | 5.95 | 5.21 | |
UnitedHealth Group Inc. | 14.44 | 13.47 | 11.55 | 12.39 | 12.82 | |
Interest Coverage, Sector | ||||||
Health Care Equipment & Services | 9.80 | 6.13 | 7.22 | 6.86 | 8.91 | |
Interest Coverage, Industry | ||||||
Health Care | 13.43 | 7.42 | 9.11 | 8.47 | 10.15 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Interest coverage = EBIT ÷ Interest expense
= 9,432 ÷ 1,334 = 7.07
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Bristol-Myers Squibb Co. interest coverage ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |
Fixed Charge Coverage
Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings (loss) attributable to BMS | 6,994 | (9,015) | 3,439 | 4,920 | 1,007 | |
Add: Net income attributable to noncontrolling interest | 20 | 20 | 21 | 27 | (32) | |
Add: Income tax expense | 1,084 | 2,124 | 1,515 | 1,021 | 4,156 | |
Add: Interest expense | 1,334 | 1,420 | 656 | 183 | 196 | |
Earnings before interest and tax (EBIT) | 9,432 | (5,451) | 5,631 | 6,151 | 5,327 | |
Add: Operating lease expense | 281 | 263 | 160 | 130 | 120 | |
Earnings before fixed charges and tax | 9,713 | (5,188) | 5,791 | 6,281 | 5,447 | |
Interest expense | 1,334 | 1,420 | 656 | 183 | 196 | |
Operating lease expense | 281 | 263 | 160 | 130 | 120 | |
Fixed charges | 1,615 | 1,683 | 816 | 313 | 316 | |
Solvency Ratio | ||||||
Fixed charge coverage1 | 6.01 | -3.08 | 7.10 | 20.07 | 17.24 | |
Benchmarks | ||||||
Fixed Charge Coverage, Competitors2 | ||||||
Abbott Laboratories | 10.21 | 6.68 | 5.14 | 4.48 | 3.47 | |
CVS Health Corp. | 3.03 | 2.75 | 2.56 | 1.27 | 3.35 | |
Danaher Corp. | 10.85 | 7.10 | 8.38 | 8.49 | 8.14 | |
Elevance Health Inc. | 8.48 | 6.10 | 7.34 | 6.28 | 5.20 | |
Intuitive Surgical Inc. | 93.66 | 58.48 | 79.65 | — | — | |
Medtronic PLC | 4.31 | 3.98 | 3.97 | 4.87 | 4.32 | |
UnitedHealth Group Inc. | 8.80 | 8.51 | 7.65 | 8.41 | 8.40 | |
Fixed Charge Coverage, Sector | ||||||
Health Care Equipment & Services | 6.19 | 4.13 | 4.87 | 4.67 | 5.51 | |
Fixed Charge Coverage, Industry | ||||||
Health Care | 9.33 | 5.42 | 6.68 | 6.31 | 7.25 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
1 2021 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= 9,713 ÷ 1,615 = 6.01
2 Click competitor name to see calculations.
Solvency ratio | Description | The company |
---|---|---|
Fixed charge coverage ratio | A solvency ratio calculated as earnings before fixed charges and tax divided by fixed charges. | Bristol-Myers Squibb Co. fixed charge coverage ratio deteriorated from 2019 to 2020 but then improved from 2020 to 2021 not reaching 2019 level. |